Ideaya enrolls first patient in phase 1 trial of IDE034 cancer drug
#Ideaya Biosciences #IDE034 #Phase 1 Trial #Cancer Drug #Antibody-drug Conjugate #PTK7/B7H3 #Clinical Development
📌 Key Takeaways
- Ideaya Biosciences enrolled first patient in phase 1 trial for IDE034 cancer drug
- IDE034 is a PTK7/B7H3 bispecific TOP1 antibody-drug conjugate
- The trial will evaluate safety, tolerability, and efficacy in advanced solid tumors
- This represents a significant milestone in Ideaya's oncology pipeline
📖 Full Retelling
Biotechnology company Ideaya Biosciences (NASDAQ:IDYA) announced today that it has enrolled the first patient in a phase 1 clinical trial for IDE034, an investigational cancer drug, at its South San Francisco headquarters. IDE034 is a PTK7/B7H3 bispecific TOP1 antibody-drug conjugate designed to target cancer cells with precision. This milestone represents a significant advancement in Ideaya's oncology pipeline, as the company continues to develop innovative therapies for difficult-to-treat cancers. The phase 1 trial will evaluate the safety, tolerability, and preliminary efficacy of IDE034 in patients with advanced solid tumors, with a focus on those whose tumors express PTK7 and/or B7H3 biomarkers. The initiation of this trial underscores Ideaya's commitment to addressing unmet medical needs in oncology through targeted therapies. Antibody-drug conjugates like IDE034 represent a promising approach in cancer treatment, as they combine the targeting ability of monoclonal antibodies with the cell-killing ability of chemotherapy drugs, potentially reducing side effects compared to traditional chemotherapy.
🏷️ Themes
Biotechnology, Clinical Trials, Cancer Treatment
📚 Related People & Topics
Chemotherapy
Treatment of cancer using drugs that inhibit cell division or kill cells
Chemotherapy (often abbreviated chemo, sometimes CTX and CTx) is the type of cancer treatment that uses one or more anti-cancer drugs (chemotherapeutic agents or alkylating agents) in a standard regimen. Chemotherapy may be given with a curative intent (which almost always involves combinations of d...
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
SOUTH SAN FRANCISCO - Ideaya Biosciences (NASDAQ:IDYA) enrolled the first patient in a phase 1 trial evaluating IDE034, an investigational PTK7/B7H3 bispecific TOP1 antibody-drug conjugate, according to a press release statement issued today.
Read full article at source